Evaxion posts $3.7M Q2 loss, advances cancer vaccine pipeline

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Evaxion posts $3.7M Q2 loss, advances cancer vaccine pipeline

Evaxion announces business update and second quarter 2026 financial results

August 20, 2026 7:30 AM EDT

COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (Evaxion), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, provides business update and announces second quarter 2026 financial results.

Business highlights (since last quarterly update)
Evaxion is making steady progress towards completing its strategic milestones for 2026. Highlights include:

Announcing the upcoming presentation of three-year clinical data for personalized cancer vaccine candidate EVX-01 at the ESMO Congress 2026Presentation of new data for EVX-04, an off-the-shelf cancer vaccine for acute myeloid leukemia... More